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One of the hallmark features of Alzheimer’s disease (AD) is deposition of the amyloid 
@-protein in extracellular neuritic plaques and within cerebral blood vessel walls. 
Similar neuropathology is observed in brains of individuals with hereditary cerebral 
hemorrhage with amyloidosis-Dutch type.6 The amyloid @-protein is an insoluble, self- 
aggregating peptide with a molecular mass of 4.2 ma.’.’ CDNA cloning studies 
revealed that the amyloid /3-protein is derived from a larger precursor protein, termed 
the amyloid @-protein precursor (APP), which is encoded by a gene located on chromo- 
some 21.’-1° Subsequent studies showed that APP is translated from at least three 
alternatively spliced mRNAs resulting in polypeptides of 695, 751 and 770 amino 
acids.IL-I3 The latter two species contain an additional insert which is structurally 
similar to the inhibitory domain of Kunitz-type serine protease inhibitors (KPI). The 
secreted form of APP containing the KPI domain has been shown by us and others 
to be identical to the serine protease inhibitor, protease nexin-2 (PN-2).14J5 The 
identity of APP and PN-2 was demonstrated by amino terminal and additional peptide 
amino acid sequences of PN-2 aligning with amino acid sequences deduced from 
cDNAs for APP. Full-length APP is normally cleaved at the carboxy terminal side of 
LysI6 in the amyloid fl-protein domain, resulting in a secreted PN-2 that contains the 
first fifteen amino acids ofthe amyloid @-protein at its carboxy terminus.’”I8 Currently, 
little is known about the physiological function( s) of PN-2 and the other APP isoforms. 
Recent findings suggest a potential physiological role for PN-Z/APP as a cerebral 
anticoagulant. 
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PN-2 is the Predominant I sohm of APP in Human Brain 
Studies have demonstrated that mRNA encoding the forms of APP that contain 
the KPI domain are present in most tissues.11-’3J9 On the other hand, mRNA encoding 
the form of APP that lacks the KPI domain is found primarily in brain and has been 
suggested to be the major isoform of APP mRNA in this tissue. In human brain two 
major APP proteins have been identified with approximate molecular masses of 120 
kDa and 105 kDa.20-22 The 120-kDa isoform of APP protein in human brain has been 
shown to contain the KPI domain based on immunoblomng studies with a polyclonal 
antiserum raised against a synthetic peptide corresponding to a region of the KPI 
domain.2’ The 105-kDa isoform ofAPP protein did not react with this same antiserum, 
suggesting that this APP isoform lacks the KPI domain.21 The seemingly abundant 
amount of APP protein that lacks the W I  domain in brain appeared to be consistent 
with the high levels of its corresponding mRNA in this tissue. 
Recently we described a qualitative and quantitative study that analyzed the differ- 
ent APP protein isoforms in human brain.23 In addition to immunoblotting analyses, 
our studies employed functional assays that were specific for WI-containing isoforms 
of APP proteins. These assays included formation of sodium dodecyl sulfate polyacryl- 
amide gel electrophoresis (SDS-PAGE) stable complexes with an 1251-labeled prote- 
asezCz6 and precipitation by trypsin-agarose. The immunoblotting and functional assays 
showed that human fibroblasts and human platelets contained a 12O-kDa, KPI- 
containing form of APP protein. On the other hand, immunoblotting showed that 
normal and AD brain contained 120-kDa and 105-kDa forms of APP protein. How- 
ever, the functional assays indicated that both forms of APP proteins in the brain 
contained the KPI domain.23 Quantitative functional assays indicated that > 80% of 
the total APP protein in human brain contains the KPI domain. The findings in this 
study were extended by functional analyses comparing APP proteins that were purified 
from brain and cerebrospinal fluid of normals and AD patients. A previous study 
indicated that < 10% of the APP proteins in cerebrospinal fluid contain the KPI 
domain.27 FIGURE 1 shows that APP proteins purified from cerebrospinal fluid formed 
< 10% of the amount of SDS-PAGE stable complexes with 1251-labeled protease than 
did APP proteins purified from brain. Similar findings were observed with purified 
APP proteins from normals and AD patients. Together, these KPI-specific functional 
assays indicate that the majority of APP in human brain contains the KPI domain, 
regardless of its molecular mass on SDS-polyacrylamide gels. 
Recent immunohistochemical and immunoblotting studies by Arai tt uf. 28 detected 
APP proteins in various tissues and cell types of the central nervous system. However, 
most nonneural tissues were notably devoid of APP immunoreactivity. Extending these 
findings we have recently conducted quantitative immunoblotting studies to determine 
the levels of PN3/APP in a variety of nonhuman primate tissues. These studies showed 
that PN-2/APP was most abundant in brain with some presence in testis and kidney 
(unpublished data). It is noteworthy that similar studies showed that protease nexin- 
1 (PN-l), a potent antithrombin, is also found primarily in brain. These studies raise 
the intriguing question as to why there is a rich and relatively exclusive investment of 
PN3/APP, as well as PN-1, in brain. 
PN-2/”P Is an Abundant Platelet Q Granule Protein and Potent 
Inhibitor of Coagulation Factor XIa 
Several findings have suggested a vascular contribution of PN-Z/APP and the 
amyloid &protein. APP mRNA transcripts have been recognized in human umbilical 
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FIGURE 1. Quantitation of WIcontaining isoforms ofAPP in human brain and cerebrospinal 
fluid. (A) Equivalent amounts of APP proteins purified from normal brain tissue (lane I), normal 
cerebrospinal fluid (lane 2), AD brain tissue (lane 3), and AD cerebrospinal fluid (lane 4)  were 
incubated with a molar excess of '251-labeled epidermal growth factor binding protein and analyzed 
by SDS-PAGE with subsequent autoradiography. (B) The high molecular weight complexes 
between 1z51-epidermal growth factor binding protein and the KPIcontaining isoforms of APP 
were quantitated by laser scanning densitometry. Purified cerebrospinal fluid APP contains < 10% 
the amount of WI-containing isoforms than purified brain APP. 
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vein endothelial cells.29 Furthermore, interleukin I, which is elevated in brain tissue 
from patients with AD and Down’s syndrome, upregulates APP mRNA in endothelial 
cells through protein kinase C.29.30 In addition, various sized PN-UAPP proteins 
between 105 and 135 kDa have been recognized in leptomeningeal and cortical blood 
vessel walls.3’ Other vascular sources for PN3/APP have been sought. The finding 
that heparinized plasma contained some PN-Z/APP immunoreactivity32 suggested that 
circulating cells in blood could be releasing this protein. Our recent studies showed 
that PN5/APP circulates in blood as a platelet a granule protein and is secreted upon 
activation of platelets by physiological a g ~ n i s t s . ~ ~  The presence of platelet 
PN-2/APP has been confirmed by three other l a b o r a t ~ r i e s . ~ ~ - ~ ~  When compared with 
other prominent cells of the intravascular compartment, platelets appear to be a 
relatively specific, intravascular source for PN-WAPP, accounting for 99% of its con- 
centration in the intravascular ~ o m p a r t m e n t . ~ ~  Platelet PN3/APP is also a major 
protein in platelets accounting for 0.5% of total platelet protein.j7 Furthermore, 
remnant APP mRNA is found in human platelets and some of the full length protein 
is present in platelet membranes.j6 Together, these studies clearly indicate that platelets 
are the major circulating repository for PN3/APP and provide an effective mechanism 
for the delivery and expression of large quantities of this protein at specific sites 
throughout the vasculature. 
Investigations by us and others have sought to identify physiologic target proteases 
that are inhibited by PN-2/APP. Kinetic inhibition studies showed that PN-2/APP is 
a potent inhibitor of several “trypsin-like” and “chymotrypsin-like” serine proteases 
including trypsin (K, = 4.2 x lo-’’ M), chymotrypsin (K, = 1.6 x lop9 M), 
epidermal growth factor binding protein (K, = 5.8 X M) and the y subunit of 
nerve growth factor (K, = 9.1 X M).’4*263”*38939 More specifically, studies defin- 
ing the protease inhibitory properties ofPN-2/APP revealed that it is a potent inhibitor 
of coagulation factor XIa (K, = 5.5 x lo-’’ M).34938 Factor XIa is the first protease 
in the intrinsic coagulation pathway whose deficiency leads to bleeding.40 The inhibi- 
tion of factor XIa by PN-2/APP was augmented by heparin suggesting that glycosami- 
noglycans may play an important role in the regulation of certain physiologic target 
proteases by PN-2/APP.34-38 Together, the findings that platelet PN-2/APP is secreted 
upon platelet activation along with other a granule constituents and it is a very effective 
inhibitor of factor XIa, support the notion that PN3/APP has a physiologic function 
in regulating h e m o s t a ~ i s . ~ ~ , ~ ~ . ~ ~ ~ ~ ~ , ~ ’  Further, its orher protease specificities suggest that 
it may play a role in regulating other proteolytic events associated with wound repair. 
Regulation of Coagulation in the Systemic and Cerebral Vasculature 
Recently, a revised hypothesis on the initiation of blood coagulation was proposed 
based on studies by Naito and F ~ j i k a w a ~ ~  nd Gailani and Broze,13 which showed that 
factor XI, the first committed hemostatic protein, is a better substrate of thrombin 
than factor XIIa in the presence of a negatively charged surface like dextran sulfate or 
glycosaminoglycans. In this revised model, coagulation is initiated by generating small 
amounts of thrombin at the site of injury via the extrinsic pathway (FIG. 2). Thrombin 
may then serve as the “trigger” to activate factor XI, which initiates the subsequent 
steps of the intrinsic pathway. Activation of the intrinsic pathway leads to the amplifi- 
cation of thrombin formation, which serves two important functions: (1) sustaining 
the activation of factor XI by a factor XIIa-independent mechanism, and (2) catalyzing 
the formation of fibrin leading to clot formation. It is noteworthy that this model 
implicates thrombin and factor XIa as two key enzymes involved with the amplification 
system of hemostasis (FIG. 2). 
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FIGURE 2A. Schematic representation of the regulation of the coagulation cascade in the 
systemic vasculature. Small amounts of thrombin generated by factor Xa via the extrinsic coagula- 
tion pathway can lead to activation of factor XI with subsequent amplification of the intrinsic 
coagulation pathway. Factor XIa can also autoactivate hrther contributing to the amplification 
of the intrinsic pathway. In the systemic vasculature, excess thrombin binds to thrombomodulin 
and converts protein C (Pc) into activated protein C (act. Pc). Optimal activity of Pc requires 
the presence of Protein S (Ps). Activated Pc-Ps complexes can inactivate coagulation factors Va 
and VIIIa via proteolysis. 
Uncontrolled activation of the coagulation cascade can cause thrombosis leading 
to stroke and infarct. Systemically, regulation of  coagulation is chiefly accomplished 
by two mechanisms, both ofwhich involve the surface of the vascular endothelium.+' 
The first anticoagulant mechanism is the heparin-antithrombin I11 system which in- 
volves glycosaminoglycans on  the surface of the vascular endothelium. The other 
key anticoagulant molecule distributed on  the plasma membrane of arterial, venous, 
capillary, and lymphatic endothelium is thrombomodulin (FIG. 2A). Thrombo- 
modulin is an integral membrane protein which functions indirectly as an anticoagulant 
due to its ability to alter the substrate specificity ofthrombin. When bound to thrombo- 
modulin, thrombin loses its specificity for fibrinogen and becomes a potent activator 
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FIGURE 2B. Schematic representation of the proposed roles of PN-1 and I"-2 in the regulation 
of the coagulation cascade in the cerebrovasculature. Excess thrombin binds to PN-1 which 
blocks its ability to cleave fibrinogen or activate factor XI. Excess factor XIa binds to PN-2 which 
inhibits its ability to activate additional factor XI and the subsequent steps of the intrinsic 
coagulation pathway. 
of protein C. Protein C is a serine protease which, in concert with protein S ,  exerts 
its anticoagulant effect by rapidly hydrolyzing coagulation factors Va and VIIIa. In 
order for thrombin to effectively activate protein in PiPo it must be bound to thrombo- 
modulin. 
In the brain, however, thrombomodulin is virtually absent from much of the 
endothelium of cerebral blood vessels.45 This finding suggests that the anticoagulant 
protein C system is not operative in the brain. Other regulatory molecules must be 
present in the brain and the cerebrovasculature to provide a means to control thrombin 
formation (FIG. 2B). As mentioned above, brain exhibits a very rich and exclusive 
investment of PN3/APP, a potent inhibitor of factor XIa. In addition, normal brain, 
particularly around cerebral blood vessels, is richly invested in PN-1, a potent inhibitor 
of thrombin.**" We propose that abundant PN3/APP and PN-1 working at the 
level of factor XIa and thrombin, respectively, could hnction in concert as major 
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intracerebral anticoagulants. Alterations in the levels or functional properties of 
PN-2/APP and/or PN-1 could lead to coagulation disorders in the brain. 
SUMMARY 
The amyloid &protein precursor (APP) is the parent molecule to the amyloid 
&protein which is a major constituent of neuritic plaques and cerebrovascular deposits 
in Alzheimer’s disease (AD). The protease inhibitor, protease nexin-2 (PN-2), is the 
secreted form of APP that contains the Kunitz protease inhibitor (KPI) domain. We 
reported that the predominant isoform of APP in human brain contains the KPI 
domain and is thus PN-2. Quantitation of PN-2/APP in various tissues revealed that 
it is primarily found in brain. Circulating blood platelets are another rich source of 
PN-2/APP. Platelet PN3/APP is contained in platelet a granules and is secreted upon 
activation of platelets by physiological agonists. Protease inhibition measurements 
demonstrated that PN-2/APP is a potent inhibitor of intrinsic blood coagulation 
factor XIa. These findings suggest that PN5/APP may play a role in the regulation 
of blood coagulation and platelets may serve as a systemic vehicle to deliver large 
amounts of this protein to sites of vascular injury. In addition, we propose that the 
rich, and relatively exclusive, investment of PN3/APP in brain suggests that it may 
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